TCGA-D8-A1JK-01A-11R-A13Q-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INFLAMMATORY_RESPONSE+0.560
- INTERFERON_GAMMA_RESPONSE+0.530
- ALLOGRAFT_REJECTION+0.520
- IL6_JAK_STAT3_SIGNALING+0.520
- MTORC1_SIGNALING+0.500
- GLYCOLYSIS+0.480
- TNFA_SIGNALING_VIA_NFKB+0.480
- HYPOXIA+0.470
- INTERFERON_ALPHA_RESPONSE+0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.430
Top 10 suppressed
- ESTROGEN_RESPONSE_EARLY-0.290
- MYC_TARGETS_V2-0.220
- ESTROGEN_RESPONSE_LATE-0.130
- MITOTIC_SPINDLE-0.080
- MYC_TARGETS_V1-0.050
- WNT_BETA_CATENIN_SIGNALING-0.040
- UV_RESPONSE_DN-0.020
- DNA_REPAIR+0.010
- UNFOLDED_PROTEIN_RESPONSE+0.030
- HEDGEHOG_SIGNALING+0.040
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-C8-A26X-01A-31R-A16F-07 | — | C | 0.910 |
| 2 | b428d434-2904-4f67-a66f-b7928e2951e3 | — | — | 0.885 |
| 3 | TCGA-AN-A0AL-01A-11R-A00Z-07 | — | E | 0.884 |
| 4 | 53D8CF8D-31BA-4CB8-A14F-5C9AB9554F5D | — | — | 0.878 |
| 5 | BS_KEA474HN | low-grade glioma | — | 0.873 |
| 6 | 0E9EAAED-A9A2-41E7-AC3A-49E94C933432 | — | — | 0.871 |
| 7 | MDT-AP-2887 | Med | Medulloblastoma | 0.871 |
| 8 | TCGA-38-4629-01A-02R-1206-07 | — | cohortA1 | 0.871 |
| 9 | TCGA-ZF-AA53-01A-11R-A39I-07 | — | — | 0.870 |
| 10 | 25C4D537-0142-4DAA-874B-BC793336DE82 | — | — | 0.869 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INFLAMMATORY_RESPONSE | 0.560 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.530 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.520 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.520 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.500 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.480 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.480 | Inavolisib | — uncovered |
| HYPOXIA | 0.470 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.450 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.430 | Inavolisib | — uncovered |
| COMPLEMENT | 0.420 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.420 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.390 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.370 | Inavolisib | — uncovered |
| COAGULATION | 0.350 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.350 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.340 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.330 | Inavolisib | — uncovered |
| APOPTOSIS | 0.320 | Idelalisib | — uncovered |